Price
No data yet.
Social Signal Score
Analyst Ratings
31 analystsRevenue
$2.08M+102.92%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Bahram Valamehr
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 161
- Beta
- 2.55
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -8.07
Financials
Revenue
$2.08M+102.9%Net Income
$-30.16MEBITDA
$-30.55MFree Cash Flow
$-23.51MEPS (diluted)
$-0.25Shares Outstanding (diluted)
120.40M+275.2%Operating Expenses
$33.22MCash & Debt
$153.77MReturn of Capital
$0.00Revenue by Segment (annual)
$31.20MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $6.65M | $-136.31M | $-1.15 |
| 2024 | $13.63M | $-186.26M | $-1.64 |
| 2023 | $63.53M | $-160.93M | $-1.64 |
| 2022 | $96.30M | $-281.72M | $-2.91 |
| 2021 | $55.85M | $-212.15M | $-2.24 |
| 2020 | $31.43M | $-173.39M | $-2.10 |
| 2019 | $10.68M | $-98.15M | $-1.43 |
| 2018 | $4.74M | $-66.60M | $-1.19 |
| 2017 | $4.11M | $-42.95M | $-1.02 |
| 2016 | $4.40M | $-33.46M | $-1.05 |
| 2015 | $2.43M | $-29.99M | $-1.18 |
| 2014 | $0.00 | $-25.88M | $-1.27 |
| 2013 | $971.0K | $-20.89M | $-1.07 |
| 2012 | $2.67M | $-14.24M | $-1.61 |
Valuation
FATEhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
70-50.00%Social Signal Score
Mentions (5)
- Newsglobenewswire.com·5d ago·Positive
Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that management will participate in the following investor conferences in the fourth quarter of 2026.
View source ↗ - Newsseekingalpha.com·33d ago·Negative
…l Clinical Updates Ahead Fate Therapeutics has initiated the phase 2 RECLAIM-LN trial of FT819 in lupus nephritis, dosing the first patient in an outpatient setting. FATE plans to open 20 trial sites by the end of 2026 and expects interim analysis data from multiple patients in H2'27, potentially accelerating enrollment. Phase 1 data for FT819 showed reductions in disease activity in systemic lupus erythematosus, including in patients with lupus nephritis.
View source ↗ - Newsglobenewswire.com·53d ago·Neutral
Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis First patient dosed in an outpatient setting, discharged the same day; multiple patients in the process of screening at several activated sites
View source ↗ - Newszacks.com·53d ago·Negative
Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates Fate Therapeutics (FATE) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to a loss of $0.29 per share a year ago.
View source ↗ - Newsglobenewswire.com·54d ago·Neutral
Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates First lupus nephritis patient dosed in RECLAIM-LN, a Phase 2 potentially registrational trial utilizing FT819, an iPSC-derived, off-the-shelf CAR T-cell therapy; patient was treated as an outpatient with same-day discharge
View source ↗
Earnings
Thu, Nov 12(in 5 weeks)
Consensus estimate $-0.27 per share
Typical surprise +6.9% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-0.25 vs $-0.25beat
- Wed, May 13$-0.26 vs $-0.29beat
- Thu, Feb 26$-0.27 vs $-0.27beat
- Thu, Nov 13$-0.27 vs $-0.29beat
- Tue, Aug 12$-0.29 vs $-0.35beat
- Tue, May 13$-0.32 vs $-0.39beat
Estimates and results for FATE via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by FATE officers and directors.
- Bought
- $669k
- Sold
- $975k
1 trade
14 trades
- Tahl Cindysold
- Valamehr Bahramsold
- Tahl Cindysold
- Valamehr Bahramsold
- Tahl Cindysold
- Valamehr Bahramsold
- Tahl Cindysold
- Valamehr Bahramsold
85 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Daniel Goldmanhouse · NY10 · disclosed Feb 24, 2023 (24d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.